Forus Therapeutics develops a biopharmaceutical platform focused on creating targeted therapies for hematologic malignancies and other cancers. The platform enhances treatment accessibility for patients, physicians, and caregivers, facilitating the delivery of effective cancer therapies and support tools.
Funding
$180M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
+4Founders
Product
Problem
Patients with hematologic malignancies and other cancers often face challenges in accessing targeted therapies and comprehensive support tools, which can hinder effective treatment and overall care. The accessibility gap impacts patients, physicians, and caregivers alike.
Solution
Forus Therapeutics is a biopharmaceutical company focused on developing and delivering differentiated, novel medicines for hematologic malignancies and other cancers. By focusing on targeted therapies, Forus aims to improve treatment outcomes and enhance the overall care experience for patients. The company facilitates the delivery of effective cancer therapies and support tools, ensuring that patients, physicians, and caregivers have access to the resources they need. Forus Therapeutics is dedicated to advancing innovative solutions in the field of oncology.
Target Audience
The primary target audience includes patients with hematologic malignancies and other cancers, as well as their physicians and caregivers.
Features
- Development of targeted therapies for hematologic malignancies.
- Focus on differentiated, novel medicines for cancer treatment.
- Facilitation of access to effective cancer therapies.
- Provision of support tools for patients, physicians, and caregivers.